Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial

@article{Bjhle2013SerumTK,
  title={Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial},
  author={Judith Bj{\"o}hle and Jenny Bergqvist and J. Simon Gronowitz and Harriet Johansson and Lena Carlsson and Zakaria Einbeigi and Barbro K. Linderholm and Niklas Loman and Martin Malmberg and Martin S{\"o}derberg and Marie Sundquist and Thomas M. Walz and M{\aa}rten Fern{\"o} and Jonas Bergh and Thomas Hatschek},
  journal={Breast Cancer Research and Treatment},
  year={2013},
  volume={139},
  pages={751-758}
}
The primary objective was to estimate serum thymidine kinase 1 (TK1) activity, reflecting total body cell proliferation rate including cancer cell proliferation, in women with loco regional inoperable or metastatic breast cancer participating in a prospective and randomized study. Secondary objectives were to analyze TK1 in relation to progression-free survival (PFS), overall survival (OS), therapy response and other tumour characteristics, including CA 15-3, widely used as a standard serum… 

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer

The rapid development of new therapies in metastatic breast cancer (MBC), entails a need for improved prognostic and monitoring tools. Thymidine kinase 1 (TK1) is involved in DNA synthesis and its

Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

TLDR
High sTK1 at BL and subsequent timepoints is associated with worse prognosis in patients with MBC starting first-line endocrine therapy (ET).

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy

TLDR
It is suggested that TK1 could be a potential prognostic, predictive and monitoring marker of early ET response in HR+/HER2neg MBC patients.

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

TLDR
Thymidine kinase 1 is a dynamic marker of resistance to palbociclib which may lead to early identification of patients in whom treatment escalation may be feasible and may stratify prognosis in patients with acquired resistance toPalbOCiclib.

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

TLDR
Serum TK1 activity is a promising pharmacodynamic marker of palbociclib in ER+ breast cancer, and its value in predicting response to CDK4/6 inhibitors warrants further investigation.

Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients

TLDR
Thymidine kinase-1 (TK1), a ubiquitous enzyme involved in the pyrimidine nucleotide recovery pathway, is a cell-proliferation marker with potential prognostic and predictive impacts in BC, suggesting a possible and important role in the stratification of BC patients.

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

TLDR
This study demonstrates the clinical validity of pTKa as a new circulating prognostic marker in ER+/HER2− MBC patients treated with endocrine therapy and palbociclib and significantly improved survival prediction.

Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer

TLDR
Pancreatic ductal adenocarcinomas reveal a significant increase in S-TK activity, which is associated with overall survival, especially in early tumor stages, and may be a useful parameter for monitoring nTx efficacy.

References

SHOWING 1-10 OF 38 REFERENCES

Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients.

  • P. BroëtS. Romain F. Spyratos
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
High TK values are an important risk factor in node-negative patients and seem to be associated with a beneficial effect of adjuvant FAC or FEC in patients who received adjUvant chemotherapy.

Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma

TLDR
Thymidine kinase 1 (TK1) might be involved in the deep lymphatic dissemination and progression of melanoma metastasis and was significantly related to deep lymph node involvement.

Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.

TLDR
The results indicate that the S-TK1 concentration is higher in patients developing distant and/or loco-regional recurrence 3 months post-surgery.

Can thymidine kinase levels in breast tumors predict disease recurrence?

TLDR
Higher TK1 levels in tumors in patients who subsequently had disease recurrence almost certainly indicate a high rate of proliferation in such tumors at the time of excision, and TK is a potentially useful marker in the management of breast cancer.

Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.

TLDR
For patients with recurrent breast cancer, high tumor TK activity is a significant marker of poor clinical outcome on tamoxifen therapy, and Elevated tumor TS activity predicts a favorable outcome for 5-FU-containing polychemotherapy when applied after tumor progression on endocrine therapy.

Prognostic importance of thymidine kinase in colorectal and breast cancer.

TLDR
TK represents a secondary tumor marker which is particularly useful for cancer disease monitoring and Interpretation of this marker must be performed only in association with evaluation of clinical status since all other possible non-specific causes of elevated serum levels must be excluded.

Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer

TLDR
The magnitude of maximum fluorodeoxyglucose uptake in primary tumors and the serum TK1 level in patients with metastatic NSCLC were found to be independent prognostic predictors of overall survival.

Prognostic of DNA‐synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1–T2, N0–N1, M0 breast cancers: A retrospective multicenter study

TLDR
Univariate analysis showed that TK, TS and their combination were predictive of poor metastasis‐free (MFS) and disease‐free survival (DFS) and that high levels of both TK and TS were associated with large tumor size, histological grade III and steroid receptor‐negative tumors.

Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients

TLDR
Two recently developed immunoassays for serum thymidine kinase 1 (TK1) activity, DiviTum and Liaison, may be used for recurrence prediction in preoperative evaluation of BC patients.